Neuroblastoma is one of the most common solid tumors in pediatrics. High-risk neuroblastoma has dismal outcomes, with only a ~50% cure rate. Patients whose cancer comes back after therapy are almost incurable. Therapies used to stimulate a patient's own immune system to fight cancer have positively changed the way we treat pediatric cancer. One therapy in particular, called chimeric antigen receptor (CAR) T cells, engineer a patients own immune system (T cells) with a receptor (CAR) that allows them to find and attack cancer cells.
